000 01109 a2200301 4500
005 20250518060815.0
264 0 _c20190919
008 201909s 0 0 jpn d
022 _a1881-6096
024 7 _a10.11477/mf.1416201387
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aOkamoto, Tomoko
245 0 0 _a[Parkinson's Disease: amantadine, zonisamide, dabrafenib].
_h[electronic resource]
260 _bBrain and nerve = Shinkei kenkyu no shinpo
_cSep 2019
300 _a953-959 p.
_bdigital
500 _aPublication Type: Journal Article
650 0 4 _aAmantadine
_xtherapeutic use
650 0 4 _aAntiparkinson Agents
_xtherapeutic use
650 0 4 _aDrug Repositioning
650 0 4 _aGenome-Wide Association Study
650 0 4 _aHumans
650 0 4 _aImidazoles
_xtherapeutic use
650 0 4 _aOximes
_xtherapeutic use
650 0 4 _aParkinson Disease
_xdrug therapy
650 0 4 _aZonisamide
_xtherapeutic use
773 0 _tBrain and nerve = Shinkei kenkyu no shinpo
_gvol. 71
_gno. 9
_gp. 953-959
856 4 0 _uhttps://doi.org/10.11477/mf.1416201387
_zAvailable from publisher's website
999 _c30097633
_d30097633